Sugi Predict

Sugi Predict / Compounds / SCHEMBL3552413

SCHEMBL3552413

SCHEMBL3552413

O=C(NCc1ccccn1)c1ccc2cccc(O)c2n1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ GLS O94925 1/20 0.51
▸ RAB9A P51151 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ PSMD14 O00487 1/20 0.50
▸ STAMBP O95630 1/20 0.50
▸ PIM1 P11309 2/20 0.49
▸ ADORA2A P29274 2/20 0.49
▸ ADORA1 P30542 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ HPGD P15428 2/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ SCN9A Q15858 1/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8342442 0.88 RAB9A (0.52) SMN1; SMN2RAB9AKDM4EKMT2APIM1
SCHEMBL8342732 0.83 ADORA2A (0.53) POLBSMN1; SMN2GLSRAB9AKDM4E
SCHEMBL8344379 0.81 COPS5 (0.52) RAB9AKDM4EKMT2APSMD14STAMBP
SCHEMBL12720952 0.79 KDM4E (0.55) SMN1; SMN2RAB9AKDM4EKMT2APIM1
SCHEMBL12720966 0.79 KDM4E (0.55) SMN1; SMN2RAB9AKDM4EKMT2APIM1
SCHEMBL10027199 0.78 KDM4E (0.61) KDM4EKMT2APIM1ALDH1A1HPGD
SCHEMBL8344444 0.78 KDM4E (0.52) SMN1; SMN2RAB9AKDM4EKMT2AALDH1A1
SCHEMBL10027203 0.78 KDM4E (0.50) SMN1; SMN2RAB9AKDM4EKMT2APIM1
SCHEMBL2203862 0.77 EGLN1 (0.74) RAB9AKDM4EALDH1A1HPGDNPC1
SCHEMBL4969813 0.76 ALDH1A1 (0.64) POLBSMN1; SMN2RAB9AKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 — — US disclosed
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 — — US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 — — US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20070265253-A1 Anti-Inflammatory Compounds NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) 2007-11-15 — — US disclosed
WO-2007118276-A1 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) PRANA BIOTECHNOLOGY LTD (AU) 2007-10-25 — — WO disclosed
EP-1789422-A1 ANTI-INFLAMMATORY COMPOUNDS NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) 2007-05-30 — — EP disclosed
US-20070037848-A1 Treatment of neurological conditions PRANA BIOTECHNOLOGY LTD. (AU) 2007-02-15 — — US disclosed
US-20070037848-A1 Treatment of neurological conditions PRANA BIOTECHNOLOGY LTD. (AU) 2007-02-15 — — US disclosed
WO-2006031134-A1 ANTI-INFLAMMATORY COMPOUNDS NEW ZEALAND INSTITUTE FOR CROP & FOOD RESEARCH LIMITED (NZ) 2006-03-23 — — WO disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN POLB 1763/4885SMN1; SMN2 92/4885GLS 74/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN POLB 1763/4885SMN1; SMN2 92/4885GLS 74/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT POLB 63/4885SMN1; SMN2 1642/4885GLS 1085/4885
US-20070265253-A1 Anti-Inflammatory Compounds TNF, PTGS1, PTGES POLB 3072/4885SMN1; SMN2 4294/4885GLS 4489/4885
US-20070037848-A1 Treatment of neurological conditions BDNF, NLN, TXNRD2 POLB 2184/4885SMN1; SMN2 238/4885GLS 567/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN POLB 1763/4885SMN1; SMN2 92/4885GLS 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.